Loading
Total declarations
Companies
▲ Purchases (9 ops.)
▼ Sales (0 ops.)
Latest filing published 08 Jun 2026 for Royalty Pharma plc. Read the official filing
Filing timeline
BuySaleVlad Coric
Insider track record
Disclosed buys
9
Disclosed sells
0
T+90 hit rate
88%
T+90 mean return
+25.3%
Across 8 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Vlad Coric: trading record in brief
This profile gathers the share dealings of Vlad Coric across 5 companies, led by Biohaven Ltd., Revance Therapeutics, Inc. and Biohaven Pharmaceutical Holding Co Ltd. In total, 28 filings cover trades dated from 25 November 2021 to 5 June 2026.
On the market, this insider has only ever bought: 9 purchases, €27.9M in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 9 share grants and 4 option exercises.
A typical purchase (the median) is worth €2.2M. Clusters matter here: 8 out of 9 purchases overlapped with buying by a colleague within 30 days. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The latest filing, published on 8 June 2026, reports a share grant in Royalty Pharma plc. The latest purchase dates back some time: it was published 335 days ago, on 17 November 2025. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Vlad Coric
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations28 total
4,545 shares0Class A Ordinary SharesSEC:0001704317-26-000006:0
33,706 sharesCommon StockSEC:0001628280-26-005907:0
14,250 shares0Common SharesSEC:0001704317-26-000002:0
333,333 shares@ US$7.507.7% of flowCommon SharesSEC:0001704317-25-000004:0
Canonical exit: 11 Feb 2026 (T+90)
7,614 shares0Class A Ordinary SharesSEC:0001802768-25-000047:0
3,184 shares0Class A Ordinary SharesSEC:0001802768-25-000023:0
5,784 shares@ US$3.65100.0% of flowCommon StockSEC:0000950170-25-015343:0
14,250 shares0Common SharesSEC:0001935979-25-000002:0
21,052 shares@ US$47.503.5% of flowCommon SharesSEC:0001935979-24-000077:0
Canonical exit: 31 Dec 2024 (T+90)
15,000 shares0Common StockSEC:0001479290-24-000085:0
121,951 shares@ US$41.0018.2% of flowCommon SharesSEC:0001562180-24-003493:0
Canonical exit: 21 Jul 2024 (T+90)
232 sharesCommon SharesSEC:0001562180-24-003336:0
2,162 sharesCommon SharesSEC:0001562180-24-002509:0
5,400 sharesCommon SharesSEC:0001562180-24-000426:0
340,908 shares@ US$22.0027.6% of flowCommon ShareSEC:0001562180-23-007246:0
Canonical exit: 3 Jan 2024 (T+90)
113,637 shares@ US$22.009.2% of flowCommon SharesSEC:0001562180-23-007246:1
Canonical exit: 3 Jan 2024 (T+90)
589 shares0Common StockSEC:0001479290-23-000059:0
5,195 shares0Common StockSEC:0001479290-23-000033:0
25,800 shares@ US$15.96881.6% of flowCommon StockSEC:0001562180-22-007386:0
Canonical exit: 29 Jan 2023 (T+90)
41,930 shares@ US$14.86652.4% of flowCommon SharesSEC:0001562180-22-007373:0
Canonical exit: 26 Jan 2023 (T+90)
853,380 shares@ US$10.5034.9% of flowCommon SharesSEC:0001562180-22-007332:0
Canonical exit: 23 Jan 2023 (T+90)
00Common SharesSEC:0001562180-22-007176:0
73,331 shares@ US$8.82342.5% of flowCommon SharesSEC:0001562180-22-007115:0
Canonical exit: 3 Jan 2023 (T+90)
46,025 shares0Common SharesSEC:0001562180-22-007103:0
461,470 shares0Common SharesSEC:0001562180-22-007074:0
25 of 28 declarations
